Akshitkumar M Mistry1, Jordan A Magarik2, Michael J Feldman2, Li Wang3, Christopher J Lindsell3, Matthew R Fusco2, Rohan V Chitale2, Gordon R Bernard4, Wesley H Self5, Todd W Rice4, Christopher G Hughes6, Eva A Mistry7, Matthew W Semler4. 1. Department of Neurosurgery, University of Louisville, Louisville, KY, USA. 2. Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA. 7. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
Background: Whether the composition of intravenous crystalloid solutions affects outcomes in adults with aneurysmal subarachnoid hemorrhage (aSAH) remains unknown. Therefore, we determined whether the use of saline is associated with lower risk of disability and death in aSAH patients compared to balanced crystalloids. Methods: We conducted a post hoc subgroup analysis of the Isotonic Solutions and Major Adverse Renal Events Trial (SMART), a pragmatic, unblinded, cluster-randomized, multiple-crossover clinical trial that enrolled 15,802 adults between June 2015 and April 2017. We compared intravenous administration of saline to balanced crystalloids in consecutively enrolled aSAH patients aged 18 years or older whose ruptured aneurysm was procedurally secured at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days obtained from a prospective institutional stroke registry. Secondary outcome included death by 90 days. Logistic or proportional odds regression models were used to test for between-group differences adjusted for age, hypertension, aSAH grade, and procedure type. Results: Of the 79 aSAH patients procedurally treated during the SMART study period, 78 were enrolled (median age, 58 years; IQR, 49 to 64.5; 64% female), with 41 (53%) assigned to saline and 37 (47%) to balanced crystalloids. Plasma-Lyte was the primary balanced crystalloid used. Among 72 patients with 90-day mRS assessment, the adjusted common odds ratio, aOR, for mRS was 0.68 (95% CI, 0.28-1.63; P=0.39), with values less than 1.0 favoring saline. By 90 days, 2/39 patients (5%) in the saline group and 9/35 (26%) in the balanced-crystalloids group had died (aOR, 0.06; 95% CI, 0.00-0.50; P=0.02). Conclusions: Among procedurally treated aSAH patients, the risk of disability or death at 90 days did not significantly differ between saline and balanced crystalloids. Death occurred less frequently with saline than balanced crystalloids.
Background: Whether the composition of intravenous crystalloid solutions affects outcomes in adults with aneurysmal subarachnoid hemorrhage (aSAH) remains unknown. Therefore, we determined whether the use of saline is associated with lower risk of disability and death in aSAH patients compared to balanced crystalloids. Methods: We conducted a post hoc subgroup analysis of the Isotonic Solutions and Major Adverse Renal Events Trial (SMART), a pragmatic, unblinded, cluster-randomized, multiple-crossover clinical trial that enrolled 15,802 adults between June 2015 and April 2017. We compared intravenous administration of saline to balanced crystalloids in consecutively enrolled aSAH patients aged 18 years or older whose ruptured aneurysm was procedurally secured at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days obtained from a prospective institutional stroke registry. Secondary outcome included death by 90 days. Logistic or proportional odds regression models were used to test for between-group differences adjusted for age, hypertension, aSAH grade, and procedure type. Results: Of the 79 aSAH patients procedurally treated during the SMART study period, 78 were enrolled (median age, 58 years; IQR, 49 to 64.5; 64% female), with 41 (53%) assigned to saline and 37 (47%) to balanced crystalloids. Plasma-Lyte was the primary balanced crystalloid used. Among 72 patients with 90-day mRS assessment, the adjusted common odds ratio, aOR, for mRS was 0.68 (95% CI, 0.28-1.63; P=0.39), with values less than 1.0 favoring saline. By 90 days, 2/39 patients (5%) in the saline group and 9/35 (26%) in the balanced-crystalloids group had died (aOR, 0.06; 95% CI, 0.00-0.50; P=0.02). Conclusions: Among procedurally treated aSAH patients, the risk of disability or death at 90 days did not significantly differ between saline and balanced crystalloids. Death occurred less frequently with saline than balanced crystalloids.
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: Vivien H Lee; Bichun Ouyang; Sayona John; James J Conners; Rajeev Garg; Thomas P Bleck; Richard E Temes; Shawna Cutting; Shyam Prabhakaran Journal: Neurocrit Care Date: 2014-08 Impact factor: 3.210
Authors: Martin Nikolaus Stienen; Menno Germans; Jan-Karl Burkhardt; Marian C Neidert; Christian Fung; David Bervini; Daniel Zumofen; Michel Röthlisberger; Serge Marbacher; Rodolfo Maduri; Thomas Robert; Martin A Seule; Philippe Bijlenga; Karl Schaller; Javier Fandino; Nicolas R Smoll; Nicolai Maldaner; Sina Finkenstädt; Giuseppe Esposito; Bawarjan Schatlo; Emanuela Keller; Oliver Bozinov; Luca Regli Journal: Stroke Date: 2018-01-15 Impact factor: 7.914
Authors: Brad E Zacharia; Andrew F Ducruet; Zachary L Hickman; Bartosz T Grobelny; Luis Fernandez; J Michael Schmidt; Reshma Narula; Lauren N Ko; Margot E Cohen; Stephan A Mayer; E Sander Connolly Journal: Stroke Date: 2009-05-21 Impact factor: 7.914
Authors: Andrew D Shaw; Carol R Schermer; Dileep N Lobo; Sibyl H Munson; Victor Khangulov; David K Hayashida; John A Kellum Journal: Crit Care Date: 2015-09-12 Impact factor: 9.097
Authors: Hector Lantigua; Santiago Ortega-Gutierrez; J Michael Schmidt; Kiwon Lee; Neeraj Badjatia; Sachin Agarwal; Jan Claassen; E Sander Connolly; Stephan A Mayer Journal: Crit Care Date: 2015-08-31 Impact factor: 9.097